Barclays
BBOT

Barclays’s BridgeBio Oncology BBOT Stock Holding History

Barclays’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.9K Buy
+212
New +$2.28K ﹤0.01% 4858

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's BBOT Position: Q1 2026 in Review

Barclays opened a new position in BridgeBio Oncology (BBOT) in Q1 2026: 212 shares worth $1.9K. The stake represents ﹤0.01% of the portfolio and ranks #4858 among its holdings.

67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Barclays held 212 shares of BridgeBio Oncology worth $1.9K as of Q1 2026.
  • BridgeBio Oncology was a new Barclays position in Q1 2026.
  • BridgeBio Oncology made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4858 holding.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.